Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Goserelin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNRHR known ✓ | P30968 | 2/20 | 0.63 |
| ▸ | ABCC2 | Q92887 | 1/20 | 0.63 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.62 |
| ▸ | C5AR1 | P21730 | 2/20 | 0.55 |
| ▸ | APLNR | P35414 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Goserelin SCHEMBL7544569 | 1.00 | GNRHR (0.63) | GNRHRABCC2PTGS1C5AR1APLNR | |
| Goserelin SCHEMBL25243029 | 1.00 | GNRHR (0.63) | GNRHRABCC2PTGS1C5AR1APLNR | |
| Goserelin SCHEMBL14193129 | 1.00 | GNRHR (0.63) | GNRHRABCC2PTGS1C5AR1APLNR | |
| Goserelin SCHEMBL29833872 | 1.00 | GNRHR (0.63) | GNRHRABCC2PTGS1C5AR1APLNR | |
| Goserelin SCHEMBL13660188 | 1.00 | GNRHR (0.63) | GNRHRABCC2PTGS1C5AR1APLNR | |
| Goserelin SCHEMBL4080889 | 1.00 | GNRHR (0.62) | GNRHRABCC2PTGS1C5AR1APLNR | |
| Goserelin SCHEMBL6094 | 0.99 | ABCC2 (0.64) | GNRHRABCC2PTGS1C5AR1APLNR | |
| Goserelin SCHEMBL14485644 | 0.99 | ABCC2 (0.64) | GNRHRABCC2PTGS1C5AR1APLNR | |
| Goserelin SCHEMBL22367929 | 0.99 | ABCC2 (0.64) | GNRHRABCC2PTGS1C5AR1APLNR | |
| Goserelin SCHEMBL6866961 | 0.99 | GNRHR (0.63) | GNRHRABCC2PTGS1C5AR1APLNR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 85465 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4748859-A2 | CHEMICALLY AND PHOTOCHEMICALLY INITIATED CELL MEMBRANE BLEBBING TO INDUCE CELL VESICLE PRODUCTION, MODIFICATIONS THEREOF, AND USES THEREOF | The Regents of the University of California (US) | 2026-05-27 | — | — | EP | claimed |
| CN-116209439-B | Cereblon protein modulators | Saint Jude Children's Research Hospital Ltd. (US) | 2026-05-26 | — | — | CN | claimed |
| WO-2026105121-A1 | ANTICANCER FORMULATIONS AND USES THEREOF | INTRAGEL THERAPEUTICS LTD. (IL) | 2026-05-21 | — | — | WO | claimed |
| EP-3841097-B1 | 2,6-BIS(((1H-BENZO[D]IMIDAZOL-2-YL)THIO)METHYL)PYRIDINE AND N2,N6-DIBENZYLPYRIDINE-2,6-DICARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS PHOSPHOINOSITIDE 3-KINASE (PI3K) INHIBITORS FOR TREATING CANCER | BIOMEDICAL RES FOUNDATION OF THE ACADEMY OF ATHENS BRFAA (GR) | 2026-05-20 | — | — | EP | claimed |
| WO-2026098706-A1 | USE IN TREATING BREAST CANCER AFTER TREATMENT WITH CDK4/6 INHIBITOR | 正大天晴药业集团股份有限公司 | 2026-05-15 | — | — | WO | claimed |
| CN-122055165-A | Combination treatment of prostate cancer with two bispecific antibodies | 詹森生物科技公司 | 2026-05-15 | — | — | CN | claimed |
| WO-2026102332-A1 | NERVE AND TUMOR HOMING AGENTS AND METHODS OF USE THEREOF | Blaze Bioscience, Inc. (US) | 2026-05-15 | — | — | WO | claimed |
| US-12624049-B2 | Salt and crystal forms of 4-amino-5-(6-(4-methylpiperazin-1-yl)-1H-benzo[d]imidazol-z-yl)thieno[2.3-b]pyridin-6(7H)-one | UNIVERSITY HEALTH NETWORK (CA) | 2026-05-12 | — | — | US | claimed |
| US-12622976-B2 | Targeting CLPTM1L for treatment and prevention of cancer | THE MEDICAL COLLEGE OF WISCONSIN, INC. (US) | 2026-05-12 | — | — | US | claimed |
| CN-122029214-A | Phospholipid drug conjugate and preparation method and application thereof | 上海弼领生物技术有限公司 | 2026-05-12 | — | — | CN | claimed |
| EP-0538443-A4 | METHODS AND FORMULATIONS FOR USE IN INHIBITING CONCEPTION AND IN TREATING BENIGN GYNECOLOGICAL DISORDERS | — | 1993-12-08 | — | — | EP | claimed |
| WO-1993015722-A1 | CONTROLLED DELIVERY OF PHARMACEUTICALS FROM PREFORMED POROUS MICROPARTICLES | SYNTEX (USA) INC. (US) | 1993-08-19 | — | — | WO | claimed |
| US-5211952-A | Drug delivery of gonadotropin hormone releasing hormones for time release | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 1993-05-18 | — | — | US | claimed |
| EP-0538443-A1 | METHODS AND FORMULATIONS FOR USE IN INHIBITING CONCEPTION AND IN TREATING BENIGN GYNECOLOGICAL DISORDERS. | UNIV SOUTHERN CALIFORNIA (US) | 1993-04-28 | — | — | EP | claimed |
| EP-0518655-A2 | Solid phase peptide synthesis | ZENECA LIMITED (GB) | 1992-12-16 | — | — | EP | claimed |
| EP-0518656-A2 | Solid phase peptide synthesis | ZENECA LIMITED (GB) | 1992-12-16 | — | — | EP | claimed |
| WO-1992018107-A1 | METHODS AND FORMULATIONS FOR USE IN INHIBITING CONCEPTION AND IN TREATING BENIGN GYNECOLOGICAL DISORDERS | THE UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 1992-10-29 | — | — | WO | claimed |
| US-5143661-A | Silicone-hardened pharmaceutical microcapsules | AMERICAN CYANAMID COMPANY (US) | 1992-09-01 | — | — | US | claimed |
| EP-0312052-A1 | Intranasal administration of polypeptides in powdered form | SYNTEX (U.S.A.) INC. (US) | 1989-04-19 | — | — | EP | claimed |
| EP-0058481-B1 | CONTINUOUS RELEASE PHARMACEUTICAL COMPOSITIONS | ZENECA LIMITED (GB) | 1986-10-01 | — | — | EP | claimed |